Renal insufficiency in the patient with chronic liver disease

Clinics in Liver Disease

Volumn 19, Issue 1, 2015, Pages 45-56

  Bozanich, Nadia K ^a   Kwo, Paul Y ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Chronic liver disease; Hepatorenal syndrome; Hyponatremia

Indexed keywords

VASOCONSTRICTOR AGENT;

ACUTE KIDNEY FAILURE; BACTERIAL PERITONITIS; CHRONIC LIVER DISEASE; HEMODIALYSIS; HEPATORENAL SYNDROME; HUMAN; KIDNEY CIRCULATION; KIDNEY DISEASE; KIDNEY INJURY; LIVER TRANSPLANTATION; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK REDUCTION; SYSTEMIC VASCULAR RESISTANCE; VASOCONSTRICTION; ACUTE KIDNEY INJURY; BACTERIAL INFECTION; CHRONIC DISEASE; COMPLICATION; LIVER DISEASE; MICROBIOLOGY; PERITONITIS;

ACUTE KIDNEY INJURY; BACTERIAL INFECTIONS; CHRONIC DISEASE; HEPATORENAL SYNDROME; HUMANS; LIVER DISEASES; PERITONITIS; RENAL CIRCULATION; VASOCONSTRICTOR AGENTS;

EID: 84927588514     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2014.09.003     Document Type: Review

References (79)

1. Gonwa T.A., Wadei H.M. Kidney disease in the setting of liver failure: core curriculum 2013. Am J Kidney Dis 2013, 62:1198-1212.
2. Nair S., Verma S., Thuluvath P.J. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002, 35:1179-1185.
3. Gonwa T.A., Klintmalm G.B., Levy M., et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995, 59:361-365.
4. Gonwa T.A., McBride M.A., Anderson K., et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us?. Am J Transpl 2006, 6:2651-2659.
5. Gines P., Schrier R.W. Renal failure in cirrhosis. NEngl J Med 2009, 361:1279-1290.
6. Bellomo R., Ronco C., Kellum J., Acute Dialysis Quality Initiative workgroup, et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212.
7. Francoz C., Nadim M.K., Baron A., et al. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. Hepatology 2014, 59:1514-1521.
8. Liangpunsakul S., Agarwal R. Renal failure in cirrhosis: is it time to change the diagnosis and classification?. Am J Nephrol 2013, 38:342-344.
9. Belcher J.M., Parikh C.R., Garcia-Tsao G. Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol 2013, 11:1550-1558.
10. Proulx N.L., Akbari A., Garg A.X., et al. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol Dial Transpl 2005, 20:1617-1622.
11. Wong F., Nadim M.K., Kellum J.A., et al. Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011, 60:702-709.
12. Arroyo V. Acute kidney injury (AKI) in cirrhosis: should we change current definition and diagnostic criteria of renal failure in cirrhosis?. JHepatol 2013, 59:415-417.
13. Kellum J., Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care 2013, 17:1-15.
14. Belcher J.M., Garcia-Tsao G., Sanyal A.J., et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013, 57:753-762.
15. Wong F., O'Leary J.G., Reddy K.R., et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 2013, 145:1280-1288.e1.
16. Schrier R.W., Arroyo V., Bernardi M., et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988, 8:1151-1157.
17. Arroyo V., Gines P., Gerbes A.L., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996, 23:164-176.
18. Martin P.Y., Ginès P., Schrier R.W. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. NEngl J Med 1998, 339:533-541.
19. Ros J., Claria J., To-Figueras J., et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002, 122:85-93.
20. Ruiz-del-Arbol L., Monescillo A., Arocena C., et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005, 42:439-447.
21. Kew M.C., Varma R.R., Williams H.S., et al. Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971, 298:504-510.
22. Wiest R., Das S., Cadelina G., et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. JClin Invest 1999, 104:1223-1233.
23. Wiest R., Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005, 41:422-433.
24. Albillos A., de la Hera A., Gonzalez M., et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003, 37:208-217.
25. Frances R., Zapater P., Gonzalez-Navajas J.M., et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008, 47:978-985.
26. Chin-Dusting J.P., Rasaratnam B., Jennings G.L., et al. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med 1997, 127:985-988.
27. Rasaratnam B., Kaye D., Jennings G., et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003, 139:186-193.
28. Okita K., Kawazoe S., Hasebe C., et al. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double-blind, placebo-controlled trial. Hepatol Res 2014, 44:83-91.
29. Torres V.E., Chapman A.B., Devuyst O., et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. NEngl J Med 2012, 367:2407-2418.
30. Garcia-Tsao G., Parikh C.R., Viola A. Acute kidney injury in cirrhosis. Hepatology 2008, 48:2064-2077.
31. Cardenas A., Gines P., Uriz J., et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001, 34:671-676.
32. Tandon P., Garcia-Tsao G. Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 2011, 9:260-265.
33. Thadhani R., Pascual M., Bonventre J.V. Acute renal failure. NEngl J Med 1996, 334:1448-1460.
34. Grewal P., Martin P. Pretransplant management of the cirrhotic patient. Clin Liver Dis 2007, 11:431-449.
35. Moreau R., Gaudin C., Hadengue A., et al. Renal hemodynamics in patients with cirrhosis: relationship with ascites and liver failure. Nephron 1993, 65:359-363.
36. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. NEngl J Med 1999, 341:403-409.
37. Follo A., Llovet J.M., Navasa M., et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994, 20:1495-1501.
38. Navasa M., Follo A., Filella X., et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998, 27:1227-1232.
39. Ruiz-del-Arbol L., Urman J., Fernández J., et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003, 38:1210-1218.
40. Perdomo Coral G., Alves de Mattos A. Renal impairment after spontaneous bacterial peritonitis: incidence and prognosis. Can J Gastroenterol 2003, 17:187-190.
41. Such J., Hillebrand D.J., Guarner C., et al. Nitric oxide in ascitic fluid is an independent predictor of the development of renal impairment in patients with cirrhosis and spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2004, 16:571-577.
42. Gines A., Escorsell A., Gines P., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105:229-236.
43. Terra C., Guevara M., Torre A., et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005, 129:1944-1953.
44. Laffi G., La Villa G., Pinzani M., et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997, 1997:530-548.
45. Montseny J.J., Meyrier A., Kleinknecht D., et al. The current spectrum of infectious glomerulonephritis. Experience with 76 patients and review of the literature. Medicine (Baltimore) 1995, 74:63-73.
46. Meyers C.M., Seeff L.B., Stehman-Breen C.O., et al. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003, 42:631-657.
47. Martin P., Fabrizi F. Hepatitis C virus and kidney disease. JHepatol 2008, 49:613-624.
48. Navarro J., García-Nieto V., Bihari D., et al. Acute renal failure. Lancet 1996, 347:478-479.
49. Jeyarajah D.R., Gonwa T.A., McBride M., et al. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant. Transplantation 1997, 64:1760-1765.
50. Angeli P., Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. JHepatol 2008, 48(Suppl 1):S93-S103.
51. Abuelo J.G. Diagnosing vascular causes of renal failure. Ann Intern Med 1995, 123:601-614.
52. Fernandez J., Navasa M., Planas R., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007, 133:818-824.
53. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648.
54. Guevara M., Gines P., Fernandez-Esparrach G., et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998, 27:35-41.
55. Gulberg V., Bilzer M., Gerbes A.L. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999, 30:870-875.
56. Kiser T.H., Fish D.N., Obritsch M.D., et al. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005, 20:1813-1820.
57. Moreau R., Durand F., Poynard T., et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002, 122:923-930.
58. Gluud L.L., Christensen K., Christensen E., et al. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2012, (9). CD005162.
59. Sanyal A.J., Boyer T., Garcia-Tsao G., et al. Arandomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008, 134:1360-1368.
60. Martin-Llahi M., Pepin M.N., Guevara M., et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008, 134:1352-1359.
61. Salerno F., Gerbes A., Gines P., et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J 2008, 84:662-670.
62. Ortega R., Gines P., Uriz J., et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002, 36:941-948.
63. Moreau R., Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003, 37:233-243.
64. Angeli P., Volpin R., Gerunda G., et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999, 29:1690-1697.
65. Wong F., Pantea L., Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004, 40:55-64.
66. Esrailian E., Pantangco E.R., Kyulo N.L., et al. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007, 52:742-748.
67. Pomier-Layrargues G., Paquin S.C., Hassoun Z., et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003, 38:238-243.
68. Duvoux C., Zanditenas D., Hézode C., et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002, 36:374-380.
69. Fernandez J., Navasa M., Garcia-Pagan J.C., et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. JHepatol 2004, 41:384-390.
70. Quinlan G.J., Martin G.S., Evans T.W. Albumin: biochemical properties and therapeutic potential. Hepatology 2005, 41:1211-1219.
71. Brinch K., Moller S., Bendtsen F., et al. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. JHepatol 2003, 39:24-31.
72. Keller F., Heinze H., Jochimsen F., et al. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 1995, 17:135-146.
73. Capling R.K., Bastani B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail 2004, 26:563-568.
74. Boyer T.D. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology 2003, 124:1700-1710.
75. Uriz J., Gines P., Cardenas A., et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. JHepatol 2000, 33:43-48.
76. Tsai M.H., Peng Y.S., Chen Y.C., et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 2006, 43:673-681.
77. Moore K.P., Wong F., Gines P., et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003, 38:258-266.
78. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001, 120:726-748.
79. McCullough P.A. Contrast-induced acute kidney injury. JAm Coll Cardiol 2008, 51:1419-1428.